Immunic (IMUX) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immunic (IMUX) has outperformed Jyong Biotech (MENS) over the past year, gaining 1.9% versus a loss of 95.3%. Immunic is the larger company by market cap ($111.0 million vs $110.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | MENS |
|---|---|---|
| Share price | $6.99 | $1.45 |
| Market cap | $111.01M | $110.24M |
| 1-day change | -5.41% | -17.14% |
| YTD return | +30.90% | -63.29% |
| 1-year return | +1.90% | -95.28% |
| 5-year return | -91.88% | — |
| EPS (TTM) | $-3.53 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-97.17M | $-4.67M |
| 52-week high | $17.43 | $38.88 |
| 52-week low | $5.06 | $1.43 |
| Distance from 52-week high | -59.90% | -96.27% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +508.73% | — |
| Average volume | 343.44K | 44.23K |
| Shares outstanding | 15.88M | 74.23M |
| Employees | 100 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed MENS by 97.2 percentage points over the past year.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
IMUX vs MENS FAQ
Which is bigger, Immunic or Jyong Biotech?
Immunic (IMUX) is larger, with a market capitalization of $111.01M compared with $110.24M for Jyong Biotech (MENS).
Which stock has performed better over the past year, IMUX or MENS?
IMUX returned +1.90% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.